Telix Pharmaceuticals Limited
TLX
$10.67
-$0.07-0.65%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 56.11% | 58.88% | 60.13% | 59.19% | 57.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 56.11% | 58.88% | 60.13% | 59.19% | 57.03% |
| Cost of Revenue | 114.75% | 106.70% | 91.97% | 83.20% | 53.91% |
| Gross Profit | 19.93% | 29.47% | 40.32% | 44.72% | 59.02% |
| SG&A Expenses | 42.55% | 48.62% | 55.34% | 63.32% | 64.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1,022.28% | -17.56% | 182.04% | 88.11% | -17.42% |
| Total Operating Expenses | 70.82% | 70.95% | 68.56% | 74.30% | 56.38% |
| Operating Income | -65.32% | -42.47% | -13.07% | -25.17% | 62.59% |
| Income Before Tax | -113.98% | -93.12% | -69.44% | -25.88% | 1,453.43% |
| Income Tax Expenses | -55.29% | -93.75% | -682.06% | -163.88% | 362.59% |
| Earnings from Continuing Operations | -121.26% | -93.08% | -64.37% | -5.02% | 736.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -121.26% | -93.08% | -64.37% | -5.02% | 736.11% |
| EBIT | -65.32% | -42.47% | -13.07% | -25.17% | 62.59% |
| EBITDA | -45.31% | -25.74% | -1.52% | -18.44% | 58.96% |
| EPS Basic | -116.13% | -75.69% | -16.87% | 34.78% | 967.21% |
| Normalized Basic EPS | -122.66% | -69.73% | 51.29% | 5.81% | 170.39% |
| EPS Diluted | -118.86% | -78.07% | -20.05% | 30.92% | 1,018.02% |
| Normalized Diluted EPS | -123.84% | -71.46% | 45.42% | 0.76% | 159.63% |
| Average Basic Shares Outstanding | 2.01% | -19.66% | -37.35% | 4.25% | 3.77% |
| Average Diluted Shares Outstanding | -2.12% | -21.79% | -37.99% | 5.86% | 6.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |